Date: This event took place on September 14, 2020
Custom webcast sponsor retains sole responsibility for content.
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) represent two ends of a spectrum of neurodegenerative conditions that share pathological features and genetic underpinnings. FTD is characterized by degeneration in frontal and anterior temporal lobes, resulting in deficits in executive function, language or social cognition, while ALS is a disease of upper and lower motor neurons that leads to progressive paralysis and death, most often by respiratory failure.
Overlapping symptoms of these two diseases reflect overlapping patterns of neurodegeneration that presumably stem from shared aspects of genetic risk and/or pathogenesis at the molecular level. One of the shared pathological and molecular hallmarks is the mislocalization of the RNA binding protein TAR DNA binding protein 43 (TDP-43) from the nucleus to the cytoplasm, where it forms insoluble protein aggregates. At the same time, nucleocytoplasmic trafficking defects at the nuclear pores have been identified not only as a commonly observed disease pathogenesis in ALS/FTD, but also other neurodegenerative diseases.
In this webcast, the speaker will discuss the latest insights into the mechanisms of dysfunctional nuclear-cytoplasmic trafficking of RNA binding proteins and how they might contribute to neurodegeneration in ALS/FTD, and likely other related neurological disorders.
- Molecular landscape in ALS/FTD: perturbation of nucleocytoplasmic transport, altered RNA metabolism and synaptic dysfunction
- The role of microglia in ALS/FTD
- Human patient-derived induced pluripotent stem cells (hiPSCs) as a disease model to study ALS/FTD
Unable to join the live event? Watch on-demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced for Atlas Antibodies by Nature Research Custom Media. The sponsor retains sole responsibility for content. About this content.
Dr. Rita Sattler, Barrow Neurological Institute
Dr. Sattler is an Associate Professor at the Barrow Neurological Institute, Phoenix, AZ. She employs patient-derived induced pluripotent stem cells differentiated into neurons and glia to elucidate mechanisms of neurodegeneration in neurodegenerative disorders, including ALS/FTD. She received her PhD from the University of Toronto and completed a postdoctoral fellowship at Johns Hopkins University.
Moderator: Sarah Hiddleston, Nature Research Custom Media
Sarah Hiddleston is a freelance journalist working with Nature Research Custom Media since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.